Immunocore Holdings (IMCR) Cash & Current Investments (2019 - 2026)

Immunocore Holdings has disclosed Cash & Current Investments across 8 years of filings, most recently posting $844.9 million for Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $844.9 million, up 0.94% year-over-year; the trailing twelve-month figure through Mar 2026 was $844.9 million (up 0.94% YoY), and the FY2025 annual result was $864.1 million, up 5.34% from the prior year.
• Cash & Current Investments came in at $844.9 million for Q1 2026 at Immunocore Holdings, down from $864.1 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $901.3 million in Q3 2024 to a low of $390.0 million in Q4 2022.
• The 5-year median for Cash & Current Investments is $844.9 million (2026), against an average of $778.9 million.
• Across the five-year window, Cash & Current Investments soared 85.33% in 2024 and declined 0.99% in 2025, its largest moves.
• Immunocore Holdings' Cash & Current Investments stood at $390.0 million in 2022, then increased by 13.48% to $442.6 million in 2023, then jumped by 85.33% to $820.3 million in 2024, then grew by 5.34% to $864.1 million in 2025, then retreated by 2.23% to $844.9 million in 2026.
• The last three Cash & Current Investments figures came in at $844.9 million (Q1 2026), $864.1 million (Q4 2025), and $892.3 million (Q3 2025), per Business Quant data.